Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Total Valuation
Elevation Oncology has a market cap or net worth of $19.01M. The enterprise value is $1.98M.
Market Cap$19.01M
Enterprise Value$1.98M
Share Statistics
Elevation Oncology has 59,223,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,223,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elevation Oncology’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -49.09%.
Return on Equity (ROE)-0.74
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-49.09%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-1.31M
Employee Count34
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elevation Oncology is -0.72. Elevation Oncology’s PEG ratio is -0.37.
PE Ratio-0.72
PS Ratio0.00
PB Ratio0.34
Price to Fair Value0.54
Price to FCF-0.72
Price to Operating Cash Flow-0.56
PEG Ratio-0.37
Income Statement
In the last 12 months, Elevation Oncology had revenue of 0.00 and earned -44.48M in profits. Earnings per share was -0.78.
Revenue0.00
Gross Profit0.00
Operating Income-44.70M
Pretax Income-44.44M
Net Income-44.48M
EBITDA-44.70M
Earnings Per Share (EPS)-0.78
Cash Flow
In the last 12 months, operating cash flow was -36.36M and capital expenditures 0.00, giving a free cash flow of -28.16M billion.
Operating Cash Flow-36.36M
Free Cash Flow-28.16M
Free Cash Flow per Share-0.48
Dividends & Yields
Elevation Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change-91.67%
50-Day Moving Average0.33
200-Day Moving Average0.55
Relative Strength Index (RSI)46.49
Average Volume (3m)1.03M
Important Dates
Elevation Oncology upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Elevation Oncology as a current ratio of 21.21, with Debt / Equity ratio of 51.87%
Current Ratio21.21
Quick Ratio21.21
Debt to Market Cap0.97
Net Debt to EBITDA0.41
Interest Coverage Ratio-37.16
Taxes
In the past 12 months, Elevation Oncology has paid 43.00K in taxes.
Income Tax43.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Elevation Oncology EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.38.
EV to Sales0.00
EV to EBITDA-0.31
EV to Free Cash Flow-0.38
EV to Operating Cash Flow-0.38
Balance Sheet
Elevation Oncology has $93.18M in cash and marketable securities with $31.13M in debt, giving a net cash position of -$62.05M billion.
Cash & Marketable Securities$93.18M
Total Debt$31.13M
Net Cash-$62.05M
Net Cash Per Share-$1.05
Tangible Book Value Per Share$1.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elevation Oncology is $1.06, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.06
Price Target Upside231.25% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast47.73%